{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T05:32:18Z","timestamp":1740720738483,"version":"3.38.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Tadalafil is a phosphodiesterase inhibitor currently approved for use in erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). While tadalafil\u2019s benefits in ED and BPH have been well-established for years, its benefits in PAH were identified only recently in major clinical trials, resulting in the recent approval of a single-tablet, combination therapy of tadalafil with an endothelin receptor antagonist for PAH. With Tadalafil\u2019s cardiovascular benefits in ED, BPH, and PAH, clinical researchers have begun investigating whether tadalafil\u2019s use extends to other cardiovascular diseases, especially heart failure (HF), an emerging epidemic in medicine. Recent research in animal models has demonstrated a potential benefit of tadalafil use in ischemic cardiomyopathy and HF, as numerous studies in mice and sheep demonstrated improved left ventricular function and contractility, with reduced adverse remodeling and hypertrophy. A retrospective cohort study identified that tadalafil use in patients with ED and coronary artery disease was associated with a significant decrease in the incidence of HF, acute myocardial infarction, and mortality compared with sildenafil or no treatment. However, a randomized controlled trial in patients with comorbid PAH and HF with preserved ejection fraction demonstrated no significant benefit with the use of tadalafil. Unfortunately, there is limited evidence from clinical trials investigating the impact of tadalafil in patients with HF with reduced or preserved ejection fraction without comorbid PAH. Further studies are needed on this topic to better identify whether tadalafil has a role in the prevention or treatment of HF.<\/jats:p>","DOI":"10.1097\/crd.0000000000000877","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:01:25Z","timestamp":1740679285000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tadalafil Use in Cardiovascular Disease"],"prefix":"10.1097","author":[{"given":"Mohammed","family":"Kallash","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, New York Medical College, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"R2-20250227","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1124\/pr.111.004515","article-title":"Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction.","volume":"63","author":"Andersson","year":"2011","journal-title":"Pharmacol Rev"},{"key":"R3-20250227","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/1756287214531639","article-title":"A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.","volume":"6","author":"Hatzimouratidis","year":"2014","journal-title":"Ther Adv Urol"},{"key":"R4-20250227","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2147\/ciia.2006.1.4.439","article-title":"Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence.","volume":"1","author":"Frajese","year":"2006","journal-title":"Clin Interv Aging"},{"key":"R5-20250227","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.eururo.2011.08.005","article-title":"Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.","volume":"60","author":"Porst","year":"2011","journal-title":"Eur Urol"},{"key":"R6-20250227","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","article-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.","volume":"61","author":"Oelke","year":"2012","journal-title":"Eur Urol"},{"key":"R7-20250227","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"R8-20250227","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1185\/03007990903210066","article-title":"Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension.","volume":"25","author":"Pepke-Zaba","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R9-20250227","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.","volume":"60","author":"Oudiz","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250227","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/674901","article-title":"Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension.","volume":"4","author":"Berman-Rosenzweig","year":"2014","journal-title":"Pulm Circ"},{"key":"R11-20250227","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1378\/chest.14-0263","article-title":"Gender differences in response to tadalafil in pulmonary arterial hypertension.","volume":"147","author":"Mathai","year":"2015","journal-title":"Chest"},{"key":"R12-20250227","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.","volume":"30","author":"Barst","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R13-20250227","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/hr.2014.28","article-title":"Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.","volume":"37","author":"Zhuang","year":"2014","journal-title":"Hypertens Res"},{"key":"R14-20250227","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension.","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20250227","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","article-title":"Randomized Trial of Macitentan\/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.","volume":"83","author":"Gr\u00fcnig","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R16-20250227","year":"2024"},{"key":"R17-20250227","doi-asserted-by":"crossref","first-page":"e003911","DOI":"10.1161\/JAHA.116.003911","article-title":"Tadalafil treatment delays the onset of cardiomyopathy in dystrophin\u2010deficient hearts.","volume":"5","author":"Hammers","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"R18-20250227","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1038\/s41598-019-42592-1","article-title":"Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure.","volume":"9","author":"Lawless","year":"2019","journal-title":"Sci Rep"},{"key":"R19-20250227","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10557-014-6559-0","article-title":"Tadalafil prevents acute heart failure with reduced ejection fraction in mice.","volume":"28","author":"Salloum","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"R20-20250227","doi-asserted-by":"crossref","first-page":"120237","DOI":"10.1016\/j.lfs.2021.120237","article-title":"Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure.","volume":"289","author":"Mora","year":"2022","journal-title":"Life Sci"},{"key":"R21-20250227","first-page":"600","article-title":"Tadalafil for treatment of combined postcapillary and precapillary pulmonary hypertension in patients with heart failure and preserved ejection fraction: a randomized controlled phase 3 study.","volume":"150","author":"Hoeper","year":"2024","journal-title":"Circulation"},{"issue":"Supplement 4","key":"R22-20250227","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1097\/JU.0000000000003251.10","article-title":"PD11-10 phosphodiesterase-5 inhibitor use and progression to heart failure in men with coronary artery disease and erectile dysfunction.","volume":"209","author":"Ha","year":"2023","journal-title":"J Urol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T18:01:32Z","timestamp":1740679292000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":21,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000877","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}